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Introduction
and increased uptake of glucose in muscle. Secondly, metformin has been shown to act as a tumor growth inhibitor, at least in part by up-regulation of AMPK activity and by downstream suppression of signaling through the mammalian Target Of Rapamycin (mTOR) [11] .
Metformin use has been linked to a decreased risk of cancer overall [13, 14] , of breast cancer [15] , and of pancreatic cancer [16] , whereas evidence for an altered risk of colorectal cancer remains conflicting; Libby [14] and Currie [13] found a decreased risk of colorectal cancer among users of metformin, whereas Yang [4] did not observe such a risk reduction. Evidence from basic science study and from a small clinical series suggests that metformin inhibits AMPK dependent development of aberrant colorectal crypt foci [17, 18] , inhibits colon carcinoma growth induced by high fat diet [19] , and inhibits colon cancer cell growth in vitro [20] as well as intestinal polyp growth in mice [21] .
To explore whether use of metformin is associated with an altered risk of colorectal cancer in diabetic patients, we conducted a large case-control analysis using the UK-based General Practice Research Database (GPRD). We additionally intended to examine the risk of colorectal cancer in relation to duration of diabetes mellitus. 
Methods

Data source
Data were derived from the UK-based General Practice Research Database (GPRD) which was established around 1987 and encompasses data on over 5 million individuals [22] . Patients enrolled in participating practices are representative of the UK with regard to age, sex, geographic distribution, and annual turnover rate.
General practitioners (GPs) have been trained to record medical information including demographic data, medical diagnoses, hospitalizations, deaths, and drug prescriptions using standard software and standard coding systems. The GPs generate prescriptions directly with the computer, and this information is automatically transcribed into the computer record. It contains the name of the preparation, instructions for use, route of administration, dose, and number of tablets for each prescription. Additionally, the GPRD holds information regarding lifestyle variables such as body mass index (BMI), smoking, and alcohol consumption. The recorded information on drug exposure and diagnoses has been repeatedly validated and proven to be of high quality [23, 24] . The GPRD has been the source of many observational studies, including research on diabetes and on antidiabetic drugs [25, 26] as well as on cancer [15, 27] . The study was approved by the Independent Scientific Advisory Committee (ISAC) for the Medicines and Healthcare products Regulatory Agency (MHRA) database research.
Study population
Using medical READ codes, we first identified all subjects in the GPRD who had an incident diagnosis of colorectal cancer below the age of 90 years between 1995 and 2009. The date of this first recorded diagnosis will be referred to as the From the base population of diabetic subjects, up to 6 controls without any evidence for colorectal cancer were identified at random for each case with colorectal cancer, matched on calendar time (same index date), age (same year of birth), sex, general practice, and number of years of active history in the GPRD prior to the index date. The same exclusion criteria were applied to controls as to cases.
Diabetes duration and exposure to metformin or other hypoglycemic agents
We assessed from the computer records the duration of diabetes prior to the index date. In the main analysis, the index date was shifted by 3 years backwards in time both for cases and controls for two reasons. First, we intended to minimize detection bias, and second, we intended to minimize potential influence of subclinical cancer on glycemic control and subsequent initiation, intensification, or change of hypoglycemic drug therapy. To study the association between a history of diabetes and the risk of developing colorectal cancer, we performed two analyses with or without index dates shifted by 3 years backwards in time. We thereby intended to stratify cancer risk by diabetes duration and to quantify the short-term effects of diabetes mellitus on diagnosis of colorectal cancer.
We further assessed use of insulin and of the oral hypoglycemic drugs metformin, sulfonylureas, thiazolidinediones, glinides, and glucosidase inhibitors prior to the index date for cases and controls. We defined several exposure levels based on the recorded number of prescriptions for oral antidiabetics prior to the index date 
Covariates and sensitivity analyses
We explored the association between various potential confounders such as hemoglobin A1C, congestive heart failure, ischemic heart disease, ischemic or hemorrhagic stroke, transient ischemic attack, arterial hypertension, dyslipidemia, and use of estrogens in relation to colorectal cancer in univariate analyses. Since these variables did not alter the relative risk estimates for the association of colorectal cancer and use of metformin by more than 10%, they were not included in the final multivariate analyses. We did adjust for diabetes duration, use of statins, NSAIDs, and aspirin prior to the index date in the final model, as well as smoking (non-smoker, current, past, or unknown) and BMI (<25, 25-29.9, >30 kg/m 2 , or unknown). We finally adjusted our analyses for mixed drug use, which means that results linking use of a particular antidiabetic drug to an altered risk of colorectal cancer were adjusted for concomitant use of other antidiabetic drugs.
In one sensitivity analysis we only included cases with colorectal cancer with recorded radio/chemotherapy, colon surgery or specific oncology codes to assess potential misclassification of cancer cases. In another sensitivity analysis we explored whether missing values for BMI or smoking status had a material impact on the relative risk estimates. Finally, we stratified the analyses by gender to explore whether effect modification was present. 
Statistical analysis
We conducted conditional logistic regression analyses using the SAS statistical software version 9.2 (SAS Institute Inc, Cary, NC) to calculate relative risk estimates as ORs with 95% confidence intervals (CIs). We considered a 2-sided pvalue of <0.05 as statistically significant. 
Results
We identified a total of 920 cases with incident colorectal cancer and 5519 matched controls. Their characteristics are displayed in Table 1 . The mean (± SD) age of cases and controls was 70.2 ± 8.6 years at the index date.
Compared with the reference group of diabetic patients who did not take metformin, the adj. ORs for metformin use of 1-9, 10-29, 30-49, or ≥50 prescriptions prior to the index date were 1.05 (95% CI 0.83-1.33, 1.05 (95% CI 0.84-1.33), 1.17 (95% CI 0.88-1.55), and 1.43 (95% CI 1.08-1.90), respectively ( Table 2 ). These findings did not materially change when we restricted the analysis to cases who had recorded colorectal surgery, radio-/chemotherapy, or another oncology code (adj. OR 1.46, 95% CI 1.03-2.06) for ≥50 prescriptions). Overall, use of sulfonylureas or insulin was not associated with an altered risk of colorectal cancer ( Table 2) . As with metformin, the findings were closely similar in the subgroup of cases with colorectal surgery, radio-/chemotherapy, or another oncology code. To assess whether our results were influenced by unknown BMI or unknown smoking status, we ran sensitivity analyses restricted to diabetic subjects with known BMI and known smoking status yielding closely similar findings (results not shown).
We finally analyzed the risk of colorectal cancer in association with use of various hypoglycemic agents in men and women separately (Table 3 ). This analysis yielded some evidence that extensive use of metformin was associated with an increased risk of colorectal cancer only in men (adj. OR 1.81, 95% CI 1.25-2.62), but not in women (adj. OR 1.00, 95% CI 0.63-1.58).
Colorectal cancer was neither meaningfully associated with cardiovascular disease nor co-morbid conditions to diabetes mellitus (Table 1) . If we stratified our analyses by diabetes duration, colorectal cancer risk was highest in patients with short-term (< 2 years) compared to longer-term diabetes mellitus (adj. OR 0.82, 95% 
Discussion
Our results provide evidence that use of metformin is not associated with a decreased risk of colorectal cancer. In our study, there was even a tendency towards an increased risk with prolonged use of metformin. These findings did not materially differ across the predefined sensitivity analyses. Of interest, our results suggest, although based on a limited number of cases and controls, that gender may play a role in the association of colorectal cancer and metformin use, since prolonged use of this drug was associated with an increased risk of colorectal cancer in men, but not in women.
Overall, use of sulfonylureas and insulin were not associated with a materially altered relative risk estimate of colorectal cancer. However, there was a trend towards a decreased risk of colorectal cancer among men but not women with ≥50 prescriptions of sulfonylureas. Again, this gender specific result has to be interpreted with caution since it is based on a small number of cases and controls.
In our study, neither short-term nor long-term duration of diabetes mellitus was associated with an altered risk of colorectal cancer when the index date was shifted by 3 years backwards in time. However, when the index date was not shifted, shortterm duration of diabetes mellitus was associated with an increased risk of colorectal cancer compared to longer-term diabetes duration. This observation is in line with the results of a recent meta-analysis. In this study, the authors reported a relative risk of 1.30 (95% CI 1.20-1.40) for colorectal cancer in association with a diagnosis of diabetes mellitus [3] . Of importance, in this study, stratification by antidiabetic drug regimen or by diabetes duration was not reported. Since it is biologically implausible that short-term but not long-term duration of diabetes mellitus should be causally associated with an altered risk of colorectal cancer, we intended to minimize potential confounding by detection bias and/or influence of worsening glycemic control due to These findings strongly argue against a causal role of metformin for prevention of a chronic disease which takes years to develop. In contrast to the findings of Currie Use of NSAIDs and aspirin were associated with a decreased risk of colorectal cancer, an observation which is consistent with a recent large prospective cohort study [7] and a meta-analysis [6] . In our study, statin use was not associated with a reduced risk of colorectal cancer, a finding which is also in line with a recent study [28] . However, results from individual trials remain conflicting and a recent metaanalysis suggested a modest protective effect for statins [10] .
Several limitations of this study should be addressed. We may have missed some colorectal cancer cases due to under-diagnosing. However, the GPRD has been used numerous times for studies on various cancers [4, 15, 27] , and previous validation studies provided convincing evidence that diagnoses are recorded with high validity [23, 29] . Since pathology data are not routinely available in the GPRD, misclassification of colorectal cancer cases might have occurred. However, when we ran a sensitivity analysis restricted to cancer cases with recorded surgery, radiotherapy, chemotherapy, or other evidence for oncologic interventions in specialized oncology clinics, the results were closely similar to the main finding.
It is possible that preclinical colorectal cancer might have influenced glycemic control and thereby affected use of hypoglycemic agents in the cases. In order to reduce the risk of such a bias, we shifted the index date by 3 years backwards in time for cases and controls. We were not in a position to adjust for various risk factors for colorectal cancer which are not routinely recorded in the GPRD, such as diet, physical activity, genetic predisposition, or a positive familial history. Except for diet, however, these risk factors are unlikely to confound the association between metformin and colorectal cancer, as they are most likely not associated with metformin use. For a certain number of cases and controls information on smoking status and BMI was lacking. However, sensitivity analyses restricted to diabetic subjects with known BMI and known smoking status yielded closely similar results.
We did adjust our analyses for diabetes duration and for concomitant antidiabetic drug use, and we assessed the role of hemoglobin A1C and comorbidities associated with diabetes, but we cannot completely rule out some residual confounding by of individuals living in the UK are white [27] .
Our population-based study has several strengths. First, we were in a position to study a large number of colorectal cancer cases in a longitudinal, well-established and validated primary care database. Due to the recording of individual prescriptions by the GPs, we were able to stratify use of antidiabetic drugs by duration of use.
Because information on diseases and drug exposure was routinely entered in the GPRD in the absence of any study hypothesis, recall bias is not an issue of concern.
We further controlled for a range of potential confounders such as BMI, smoking status, comorbidities, and drug therapies, most importantly use of NSAIDs, aspirin, and statins. By shifting the index date three years backwards in time we minimized the influence of cancer-associated metabolic changes and subsequent modifications of the antidiabetic therapy. Lastly, by excluding all patients with less than 3 years of recorded history in the database prior to the index date we reduced the risk of including prevalent rather than incident cancer cases.
In conclusion, this large observational study provides evidence that use of metformin is not associated with a decreased risk of colorectal cancer; there was even a tendency towards an increased risk of colorectal cancer in men, but not in women. Use of insulin or sulfonylureas was not associated with a materially altered risk of colorectal cancer. 
